U.S. Paper and Forestry Products Stock News

In May 2026, ANI Pharmaceuticals voluntarily initiated a Class II recall of 3,964 cartons of Estradiol Gel 0.1% across the US after the FDA reported defective packets that were empty or partially filled. At the same time, the company reported strong first-quarter 2026 results, raised its full-year revenue guidance to between US$1.08 billion and US$1.14 billion, and introduced a US$100 million share repurchase program, highlighting management’s confidence despite operational issues. We’ll...

In its recently reported fiscal second quarter, Energizer Holdings posted adjusted earnings that surpassed expectations, helped by tariff refunds and ongoing margin initiatives even as overall net sales declined. Separately, Aqua Capital, Ltd. disclosed an open-market purchase of 38,006 Energizer shares, bringing its direct holding to 7,200,000 shares and underscoring concentrated institutional interest alongside the company’s margin and pricing efforts. We’ll now examine how Energizer’s...

Synchrony Financial (SYF) is in focus after expanding its CareCredit offering to LiveLoveSpa.com. The move brings flexible financing directly into online cosmetic and wellness checkouts as beauty eCommerce continues to see strong consumer interest. See our latest analysis for Synchrony Financial. The CareCredit expansion comes as Synchrony’s 1-year total shareholder return of 25.26% contrasts with a share price that is down 16.39% year to date, suggesting earlier gains are being reassessed...

Jack Henry & Associates (NasdaqGS:JKHY) has announced that Board Chair David Foss will retire, with Matt Flanigan named as his successor. The transition follows a long period in which Foss has been closely involved in shaping the company’s direction and governance. For investors tracking NasdaqGS:JKHY, this boardroom change comes at a time when the stock is trading at $130.73 and has been under pressure, with the share price down 26.7% year to date and over the past 1 year. Over longer...

Talos Energy (NYSE:TALO) has closed its Zama transaction, reshaping its offshore Mexico portfolio. The company has secured new Gulf of Mexico leases, expanding its offshore project inventory. Talos reported Q1 results ahead of expectations, supported by strong new well productivity. Talos Energy comes into this news cycle with the stock trading at $15.3 and up 36.0% year to date. The share price is also up 94.2% over the past year, while the 5 year return is down 6.7%. This highlights both...

Century Communities (CCS) has been busy rolling out new communities in South Austin, Crestview, and Radcliff, giving investors a fresh look at how the company is positioning its homebuilding footprint. See our latest analysis for Century Communities. Despite a string of community launches in Texas, Florida and Kentucky, Century Communities' recent momentum is mixed, with a 1-month share price return of 5.54% and a 3-month share price return that is down 8.48%, while the 1-year total...

In late May and early June 2026, Pfizer reported detailed Phase 3 data at ASCO showing its BRAFTOVI, TALZENNA and LORBRENA regimens delivered statistically significant improvements in progression and survival outcomes across colorectal, prostate and lung cancers, with safety profiles largely consistent with prior experience. These multi-tumor results underscore how Pfizer’s oncology portfolio is moving beyond single‑asset wins toward a broader, biomarker‑driven franchise spanning targeted...

Quarterly results put Icahn Enterprises in focus Icahn Enterprises (IEP) just released quarterly results that combined a higher Indicative Net Asset Value tied to its CVI holdings with a GAAP net loss and a fresh cash or unit distribution decision for unitholders. See our latest analysis for Icahn Enterprises. The latest quarterly update has been met with a relatively muted reaction, with the 1-day share price return of 0.67% and 7-day share price return of 0.54% sitting against a 30-day...

Regeneron Pharmaceuticals (REGN) is back in focus after expanding its cancer research partnership with CytomX Therapeutics and reporting early clinical results for Lynozyfic in light chain amyloidosis, which together have supported fresh interest in the stock. See our latest analysis for Regeneron Pharmaceuticals. Despite the positive reaction to the CytomX expansion and Lynozyfic data, Regeneron’s 1-day share price return of 1.58% sits against a year-to-date share price decline of 19.01%...

Daqo New Energy’s subsidiary Daqo Energy Technology (Shanghai) Co. Ltd. has signed an agreement to build a new Kunshan manufacturing base focused on R&D, production, and sales of next-generation energy solutions for AI data centers, including energy storage systems, solid-state transformers, circuit breakers, and batteries, with Phase 1 investment of about RMB 2,100 million and a preliminary total of about RMB 6.00 billion, although the future impact on performance remains uncertain. This...

Intel (INTC) just put its AI data center story front and center, unveiling rackscale AI infrastructure, new Xeon 6+ CPUs built on its 18A process, and partnerships with Foxconn, SambaNova, Siemens, Hitachi, and others. See our latest analysis for Intel. The latest AI rackscale push and Foxconn partnership come after a sharp run, with the 90 day share price return of 157.44% and a very large 1 year total shareholder return of 459.18%. Recent 7 day weakness hints at some cooling momentum after...

Wondering if Carrier Global at around US$68.54 is offering fair value or a potential mispricing opportunity? This article breaks down what the current share price might be telling you. The stock has recently moved, with returns of 7.4% over the last week, 6.8% over the last month, and 28.1% year to date. The return over the past year is down 2.6%, and up 56.6% over three years and 60.3% over five years. Recent coverage around Carrier Global has focused on its role in the building and HVAC...

Wondering whether Everpure at US$78.51 is offering good value or asking too much of future expectations? This article walks through what the current price might be implying about the company. The stock has returned 7.5% over the past week, 5.2% over the last month, 13.8% year to date and 43.8% over the past year, with a very large gain over five years of about 4x. Recent coverage around Everpure has focused on its role in the broader tech sector and how investors are reassessing growth...

Recent performance and context for Interparfums (IPAR) Interparfums (IPAR) has been on investors’ radar after a mixed period for the stock, with a modest gain in the past day contrasting with weaker moves over the past week and past 3 months. Over the past month the share price declined about 3%, and over the past 3 months it fell roughly 6%, while the stock is still up about 4% year to date. Over the past year, the total return declined about 33%, and over 3 years it declined about 29%,...

In early June 2026, New Jersey and the city of Newark filed lawsuits against GEO Group over alleged inhumane, unsanitary conditions at the Delaney Hall immigration detention facility and the company’s refusal to allow full state health inspections. The joint legal pressure from state and municipal authorities not only targets Delaney Hall’s operations but also elevates GEO Group’s regulatory and reputational exposure across its broader detention portfolio. We’ll examine how the legal push...

In early June 2026, Samsara Inc. reported first-quarter revenue of US$478.84 million, up from US$366.88 million a year earlier, and moved from a net loss of US$22.12 million to net income of US$44.51 million, with basic and diluted earnings per share both improving from a loss of US$0.04 to earnings of US$0.08. The company also issued guidance pointing to continued revenue growth and ongoing GAAP profitability for the second quarter and full fiscal 2027, highlighting momentum in annual...

Wondering whether Onto Innovation at around US$274.76 is still reasonably priced after its strong run, or if you might be turning up late to the story. The stock has returned 6.2% over the past week, is down 9.9% over the past month, and sits on gains of 65.6% year to date and 191.3% over the past year, which can change how investors think about both upside and risk. Recent coverage around Onto Innovation has focused on its role within the semiconductor sector and how investors are reacting...

Swarmer (NasdaqCM:SWMR) and Powerus have signed a Memorandum of Understanding to integrate Swarmer’s drone autonomy software into air and maritime autonomous systems. The collaboration targets defense, counter UAS, border security, and critical infrastructure protection use cases. The agreement extends Swarmer’s technology beyond its core drone market into broader multi domain autonomous platforms. Swarmer, trading at $72.81 under ticker NasdaqCM:SWMR, is coming off strong recent share...

Morgan Stanley (NYSE:MS) is opening its ShareWorks and Equity Edge stock administration platforms to autonomous AI agents, giving external tools direct access to key equity management workflows. The bank is also taking lead underwriting roles in planned AI and quantum technology IPOs, including Anthropic and Quantinuum. These moves put Morgan Stanley at the center of AI integration in equity administration and capital markets for next generation technology companies. Morgan Stanley enters...

Recent performance snapshot Principal Financial Group (PFG) has drawn attention after recent share price moves, with the stock last closing at US$103.51. Investors are weighing this level against its recent returns, profitability profile, and current valuation signals. See our latest analysis for Principal Financial Group. The recent 2.3% 1 day share price return adds to a steady trend, with a 90 day share price return of 12.2% and a 5 year total shareholder return of 92.2%. This indicates...

At the 2026 American Thoracic Society conference held earlier this year, Insmed showcased encouraging post‑hoc Phase III data for Brinsupri, its first‑to‑market DPP‑1 inhibitor for non‑cystic fibrosis bronchiectasis, while also granting inducement stock awards to 103 new employees under its 2025 Inducement Plan. The combination of positive clinical signals for Brinsupri and expanded equity‑based hiring underscores Insmed’s effort to build both medical leadership and internal capabilities...

MBX Biosciences recently outlined its participation at the Jefferies Global Healthcare Conference in New York and scheduled a June 12, 2026 investor webcast and call to discuss new once-weekly canvuparatide data from ENDO 2026, including one-year open-label extension and full 12-week Phase 2 Avail trial results. These upcoming endocrinology-focused presentations highlight canvuparatide’s central role in MBX Biosciences’ pipeline and could refine how investors assess the company’s clinical...

NESR shelf registration and what it could mean for investors National Energy Services Reunited (NESR) filed a shelf registration to potentially issue up to $729.6 million in ordinary shares, or 28,257,859 securities, giving the company added flexibility around future capital raising. See our latest analysis for National Energy Services Reunited. The shelf registration lands after a strong run in the stock, with a 90 day share price return of 21.43% and a year to date share price return of...

JD.com (JD) has drawn fresh attention after its 2026 618 Grand Promotion logged record customer participation and broad online and offline growth, helping the stock rebound following recent pressure in key categories. See our latest analysis for JD.com. At a share price of $29.19, JD.com has recently swung between pressure from weaker electronics and home appliance sales and renewed interest tied to the 2026 618 Grand Promotion and margin gains in JD Retail, with short term share price...